ORGO Q3 2023 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$355M

Q3 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$109M-7.1% YoY

Gross Profit

$83M76.2% margin

Operating Income

$8M7.4% margin

Net Income

$3M2.9% margin

EPS (Diluted)

$0.02

QoQ Revenue Growth

-7.5%

Cash Flow

Operating Cash Flow

$17M

Free Cash Flow

$11M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$463M

Total Liabilities

$186M

Stockholders' Equity

$277M

Cash & Equivalents

$98M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$109M	$117M	-7.1%
Gross Profit	$83M	$91M	-8.8%
Operating Income	$8M	$2M	+352.5%
Net Income	$3M	$215,000	+1373.0%

Revenue Segments

Advanced Wound care

$101M93%

Surgical and Sports Medicine

$7M7%